Sagimet Biosciences Highlights Breakthrough Therapy Designation & China NDA Acceptance for Denifanstat

summarizeSummary

Sagimet Biosciences' annual report reveals major progress for denifanstat, including FDA Breakthrough Therapy status for MASH and China NDA acceptance for acne, alongside establishing a new $75 million ATM offering for liquidity.

check_boxKey Events

• FDA Breakthrough Therapy Designation for Denifanstat

  In October 2024, denifanstat received FDA Breakthrough Therapy designation for non-cirrhotic MASH with moderate to advanced liver fibrosis, indicating potential for expedited development and review.

• China NMPA Accepts NDA for Denifanstat in Acne

  Sagimet's partner, Ascletis, had its New Drug Application for denifanstat (ASC40) for moderate to severe acne accepted by the China National Medical Products Administration (NMPA) in December 2025, following positive Phase 3 results.

• New At-The-Market (ATM) Offering Program Established

  The company entered into a Sales Agreement in August 2025 to sell up to $75.0 million of Series A common stock through an ATM offering, providing significant capital raising flexibility, though no shares were sold in 2025.

• Phase 1 PK Trial Completed for MASH Combination Therapy

  A Phase 1 pharmacokinetic trial for a combination of denifanstat and resmetirom for F4-stage MASH was completed in December 2025, showing good tolerability and no safety signals, with a Phase 2 efficacy trial planned for H2 2026.

auto_awesomeAnalysis

Sagimet Biosciences' annual report for fiscal year 2025 details significant advancements for its lead drug candidate, denifanstat. The company received FDA Breakthrough Therapy designation in October 2024 for non-cirrhotic MASH with moderate to advanced liver fibrosis, a key regulatory milestone that could expedite its development and review. Additionally, its partner Ascletis secured NMPA acceptance for a New Drug Application in China for denifanstat in moderate to severe acne in December 2025, following positive Phase 3 trial results. The company also completed a Phase 1 PK trial for a denifanstat and resmetirom combination in MASH, with plans for a Phase 2 efficacy trial in H2 2026. To support ongoing operations and future development, Sagimet established a new at-the-market offering program in August 2025, allowing it to sell up to $75.0 million in Series A common stock, providing significant funding flexibility. While the company reported an increased net loss of $51.0 million in 2025, this is typical for a clinical-stage biotech, and its existing cash and marketable securities are projected to fund operations for at least the next 12 months.